Related Experiment Videos
Antibody response to pneumococcal vaccination in the elderly
1WHO Collaborating Centre for Reference and Research on Pneumococci, Statens Serum-institut, Copenhagen, Denmark.
Zentralblatt Fur Bakteriologie : International Journal of Medical Microbiology
|April 1, 1991
Summary
Elderly individuals show a reduced antibody response to pneumococcal vaccination, specifically for anti-type 2 antibodies. This study compared antibody concentrations after Pneumovax 23 vaccination in older adults versus younger adults.
Area of Science:
- Immunology
- Gerontology
- Vaccinology
Background:
- Pneumococcal infections pose a significant health risk to the elderly.
- Pneumococcal polysaccharide vaccines (PPSV23) are recommended for older adults to prevent invasive pneumococcal disease.
- Understanding the antibody response in the elderly is crucial for vaccine efficacy.
Purpose of the Study:
- To evaluate the antibody response to primary pneumococcal vaccination in healthy elderly individuals.
- To compare the antibody concentrations post-vaccination between elderly and younger adult populations.
Main Methods:
- Twenty healthy individuals aged 60 years or older were vaccinated with Pneumovax 23.
- Blood samples were collected pre- and post-vaccination (4 weeks after).
- Pneumococcal antibody concentrations were measured using ELISA and compared to a younger adult cohort.
Main Results:
- Significantly lower anti-type 2 pneumococcal antibody concentrations were observed in the elderly group after vaccination.
- No other significant differences in pre- and post-vaccination antibody levels or fold increases were found between the elderly and younger groups.
- This suggests a specific impairment in the antibody response to certain pneumococcal serotypes in older adults.
Conclusions:
- The elderly exhibit a diminished antibody response to specific pneumococcal serotypes following vaccination with Pneumovax 23.
- While overall antibody levels may be comparable, the response to certain types is impaired in older adults.
- Further research may be needed to optimize pneumococcal vaccination strategies for the aging population.